4574 TAIKO PHARMACEUTICAL CO., LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4574

TSE Prime

TAIKO PHARMACEUTICAL CO., LTD.

291

JPY

-2

(-0.68%)

Mar 16, 9:00 am JST

1.82

USD

Mar 15, 8:00 pm EDT

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2022	5,040	-3,079	-3,352	-4,895	-112.3	0	Feb 10, 2023	J-GAAP
Dec, 2023	6,120	-1,005	-1,248	-3,611	-76.3	0	Feb 9, 2024	J-GAAP
Dec, 2024	6,292	629	688	898	17.9	0	Feb 13, 2025	J-GAAP
Dec, 2025	6,397	459	482	923	18.4	3.30	Feb 13, 2026	J-GAAP
Dec, 2026 Guidance	7,200	500	520	550	11.0	3.50	Feb 13, 2026	J-GAAP
YoY	+12.6%	+8.9%	+7.9%	-40.4%	-40.4%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2021	Feb 12, 2021	22,000	4,500	4,400	3,100	20	J-GAAP
	Aug 6, 2021	12,500	-2,000	-3,400	-2,800	0	J-GAAP
Results	Feb 18, 2022	11,299	-4,947	-6,131	-9,594	0	J-GAAP
Dec, 2022	Feb 18, 2022	Available in future release
	Aug 12, 2022
Results	Feb 10, 2023
Dec, 2023	Feb 10, 2023
	Nov 10, 2023
Results	Feb 9, 2024
Dec, 2024	Feb 9, 2024
	Mar 7, 2024
	Aug 9, 2024
Results	Feb 13, 2025
Dec, 2025	Feb 13, 2025
	Aug 20, 2025
	Nov 11, 2025
Results	Feb 13, 2026
Dec, 2026	Feb 13, 2026	7,200	500	520	550	3.5	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct, 2004	4,713	－	Available in future release
Mar, 2005 Changed	1,609	－
Mar, 2006	5,065	+214.8
Mar, 2007	4,935	-2.6
Mar, 2008	5,540	+12.3
Mar, 2009	6,094	+10.0
Mar, 2010	8,816	+44.7
Mar, 2011	4,619	-47.6
Mar, 2012	6,683	+44.7
Mar, 2013	7,443	+11.4
Mar, 2014	9,947	+33.6
Mar, 2015	8,978	-9.7
Mar, 2016	8,327	-7.3
Mar, 2017	8,294	-0.4
Mar, 2018	9,459	+14.0
Mar, 2019	10,418	+10.1
Mar, 2020	14,966	+43.7
Dec, 2020 Changed	17,582	－
Dec, 2021	11,299	-35.7
Dec, 2022	5,040	-55.4
Dec, 2023	6,120	+21.4
Dec, 2024	6,292	+2.8
Dec, 2025	6,397	+1.7
Dec, 2026 Guidance	7,200	+12.6	500	+8.9	520	+7.9	11.0	-40.2

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2024	6,292	629	10.0	12.22	6.87	0.48	17.9
Dec, 2025	6,397	459	7.18	11.20	7.33	0.51	18.4
Dec, 2026 Guidance	7,200	500	6.94	6.46	4.48	0.59	11.0

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	14,966	3,824	3,633	2,453	57.6
Fiscal Year	Mar, 2020	Mar, 2020	Mar, 2020	Mar, 2020	Mar, 2020

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2023	2,488	-396	-510	-514	-11.4	0	Aug 10, 2023	J-GAAP
Jan - Jun, 2024	2,860	482	528	764	15.2	0	Aug 9, 2024	J-GAAP
Jan - Jun, 2025	2,412	46	20	279	5.6	0	Aug 8, 2025	J-GAAP
Jan - Jun, 2026 Guidance	ー	ー	ー	ー	－	0	Feb 13, 2026	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Jun, 2023	Feb 10, 2023	ー	ー	ー	ー	－	J-GAAP
- - - - - Results	Aug 10, 2023	2,488	-396	-510	-514	0	J-GAAP
Jun, 2024	Feb 9, 2024	Available in future release
Results	Aug 9, 2024
Jun, 2025	Feb 13, 2025
Results	Aug 8, 2025
Jun, 2026	Feb 13, 2026	ー	ー	ー	ー	0	J-GAAP

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2023	-1,005	859	-307	1,166	1,539	5,244	39.67	J-GAAP
Dec, 2024	629	357	362	-5	-1,181	4,532	35.09	J-GAAP
Dec, 2025	459	956	814	142	-1,227	4,256	34.69	J-GAAP

Actual Performance and Financial Trends

Historical Performance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	6,120	-1,005	-1,248	-3,611	-76.3	0	Feb 9, 2024	J-GAAP
Dec, 2024	6,292	629	688	898	17.9	0	Feb 13, 2025	J-GAAP
Dec, 2025	6,397	459	482	923	18.4	3.30	Feb 13, 2026	J-GAAP
YoY	+1.7%	-27.0%	-29.9%	+2.8%	+2.7%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	1,377	214	229	472	9.4	15.5	May 10, 2024	J-GAAP
Apr - Jun, 2024	1,483	268	299	292	5.8	18.1	Aug 9, 2024	J-GAAP
Jul - Sep, 2024	1,719	244	177	-50	-1.0	14.2	Nov 8, 2024	J-GAAP
Oct - Dec, 2024	1,713	-97	-17	184	3.7	-5.7	Feb 13, 2025	J-GAAP
Jan - Mar, 2025	1,150	44	11	292	5.8	3.8	May 9, 2025	J-GAAP
Apr - Jun, 2025	1,262	2	9	-13	-0.3	0.2	Aug 8, 2025	J-GAAP
Jul - Sep, 2025	1,817	278	305	390	7.8	15.3	Nov 11, 2025	J-GAAP
Oct - Dec, 2025	2,168	135	157	254	5.1	6.2	Feb 13, 2026	J-GAAP
YoY	+26.6%	－	－	+38.0%	+37.9%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2021	3,271	－	Available in future release
Apr - Jun, 2021	1,835	－
Jul - Sep, 2021	3,249	－
Oct - Dec, 2021	2,944	－
Jan - Mar, 2022	621	-81.0
Apr - Jun, 2022	1,236	-32.6
Jul - Sep, 2022	1,532	-52.8
Oct - Dec, 2022	1,651	-43.9
Jan - Mar, 2023	1,167	+87.9
Apr - Jun, 2023	1,321	+6.9
Jul - Sep, 2023	1,929	+25.9
Oct - Dec, 2023	1,703	+3.1
Jan - Mar, 2024	1,377	+18.0
Apr - Jun, 2024	1,483	+12.3
Jul - Sep, 2024	1,719	-10.9
Oct - Dec, 2024	1,713	+0.6
Jan - Mar, 2025	1,150	-16.5
Apr - Jun, 2025	1,262	-14.9
Jul - Sep, 2025	1,817	+5.7
Oct - Dec, 2025	2,168	+26.6	135	－	157	－	5.1	+37.8

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	6,615	2,757	2,702	1,870	43.6
Fiscal Year	Dec, 2020	Jun, 2020	Jun, 2020	Jun, 2020	Jun, 2020

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2023	134.93	51.0	13,220	6,739	1,628	0.48	Feb 9, 2024	J-GAAP
Dec, 2024	158.67	61.7	12,914	7,964	2,526	0.25	Feb 13, 2025	J-GAAP
Dec, 2025	169.51	69.4	12,270	8,518	3,450	0.10	Feb 13, 2026	J-GAAP

TAIKO PHARMACEUTICAL CO., LTD.(4574) Financial Results